Effect of Antiallergic Agents and Bronchial Hypersensitivity in Short-term Bronchial Asthma (5)

Effect of Antiallergic Agents and Bronchial Hypersensitivity in Short-term Bronchial Asthma (5)Improvement of Bronchial Hypersensitivity in the Short-term Cases Treated with Antiallergic Agents
We then examined the number of improved cases in the short- and the long-term cases treated with antiallergic agents. As shown in Table 2, improvement of bronchial hypersensitivity was observed in 8 of 11 (73 percent) short-term cases (A group), and 3 of 13 (23 percent) long-term cases (B group). No difference in patient characteristics existed between the improved and unimproved cases in the A and B groups. No patient improved in the two groups (C and D) which were not treated with antiallergic agents. The individual changes in the histamine threshold before and after administration of antiallergic agents are shown in Figure 1. A significant increase in the histamine threshold was observed only in group A (912.2 vs 6334.7 p,g/ml).
We next examined the relationship between FEV, and bronchial hypersensitivity. As shown in Table 3, a significant improvement in %FEV, (85.1 vs 96.2 percent) and PC^ (603.7 vs 5046.5 |xg/ml) was observed only in group A. No significant change in the %FEV, or the PC*) was observed in the other three groups. flovent inhaler
In order to exclude the possibility that the improvement of bronchial hypersensitivity might be due to the improvement of baseline FEV,, we examined the rate of bronchial hypersensitivity-improved cases whose change in baseline FEV, was less than 10 percent.

Table 2—Profiles of Bronchial Asthma Patients in Four Groups

Group M:F Extrin:Intrin Age, yr Duration of Illness AdministrationPeriod
A Short-term cases with antiallergic agents Improved (n = 8) 4:4 4:4 35.5 (26-72) 7.0 (1-12) mo 5.3 (3-9) mo
Unimproved (n = 3) 3:0 2:1 43.3 (30-52) 6.3 (M2) mo 5.7 (4-7) mo
Total (n= 11) 7:4 6:5 37.6 ± 15.0 6.8±4.5 mo 5.4 ±2.0 mo
B Long-term cases with antiallergic agents Improved (n = 3) 1:2 1:2 34.3 (26-50) 10.3 (3-25) yr 7.0 (2-10) mo
Unimproved(n = 10) 8:2 6:4 34.7 (21-54) 9.2 (2-19) yr 5.5 (2-13) mo
Total (n= 13) 9:4 7:6 34.6±9.9 9.5±9.7 yr 5.8 ±3.4 mo
C Short-term cases without antiallergic agents Unimproved (n = 4) 3:1 3:1 38.0 ±10.8 3.8 ±2.5 mo 4.0 ±2.0 mo
D Long-term cases without antiallergic agents Unimproved (n = 9) 6:3 5:4 45.7±22.7 17.3 ± 23.5 yr 7.1 ±5.6 mo

Table 3—Changes in %FEVX and PC& in Four Groups

Group %FEV„ %* PC*,, jig/ml
Before After Before After
A(n = 11) 85.1 ±16.8 96.2± 10.lt 603.7 (2.78 ±0.52)$ 5046.5(3.70±0.42)§
B(n = 13) 79.9 ±13.2 81.6±20.2 389.0 (2.59 ±0.48) 638.1 (2.80 ±0.65)
C(n = 4) 83.9± 17.1 86.3 ±24.7 875.2 (2.93 ±0.48) 618.3 (2.73 ±0.28)
D(n = 9) 72.6 ±20.9 78.3 ±25.7 307.1 (2.49 ±0.67) 441.4 (2.64 ±0.59)

Figure-1

Figure 1. Individual changes in histamine threshold in four groups. Open circles, bronchial hypersensitivity-improved case; closed circles, bronchial hypersensitivity-unimproved case.


Category: Asthma

Tags: Asthma, bronchial hypersensitivity, histamine inhalation